OBJECTIVE: Bronchial thermoplasty (BT) can provide relief for patients with severe, uncontrolled asthma despite maximal medical therapy. However, it is unclear whether BT is safe in patients with very severe airflow obstruction. METHODS: We performed BT in eight patients with severe asthma as defined by Expert Panel Report 3 (EPR-3) guidelines who were poorly controlled despite step 5 therapy. Data were available on each subject for 1 year prior to and 15-72 weeks following BT. RESULTS: The mean (±SEM) pre-bronchodilator forced expiratory volume in one second (FEV(1)) prior to BT was 51.8 ± 8.6% of predicted, and the mean (±SEM) number of hospitalizations for asthma in the year prior to BT was 2.9 ± 1.2. No subject had an unexpected severe adverse event due to BT. Among the eight patients with follow-up of at least 15 weeks, there was no significant decline in FEV(1) (p = .4). CONCLUSION: We suggest that BT may be safe for asthma patients with severe airflow obstruction and higher hospitalization rates than previously reported.
OBJECTIVE: Bronchial thermoplasty (BT) can provide relief for patients with severe, uncontrolled asthma despite maximal medical therapy. However, it is unclear whether BT is safe in patients with very severe airflow obstruction. METHODS: We performed BT in eight patients with severe asthma as defined by Expert Panel Report 3 (EPR-3) guidelines who were poorly controlled despite step 5 therapy. Data were available on each subject for 1 year prior to and 15-72 weeks following BT. RESULTS: The mean (±SEM) pre-bronchodilator forced expiratory volume in one second (FEV(1)) prior to BT was 51.8 ± 8.6% of predicted, and the mean (±SEM) number of hospitalizations for asthma in the year prior to BT was 2.9 ± 1.2. No subject had an unexpected severe adverse event due to BT. Among the eight patients with follow-up of at least 15 weeks, there was no significant decline in FEV(1) (p = .4). CONCLUSION: We suggest that BT may be safe for asthmapatients with severe airflow obstruction and higher hospitalization rates than previously reported.
Authors: Gerard Cox; John D Miller; Annette McWilliams; J Mark Fitzgerald; Stephen Lam Journal: Am J Respir Crit Care Med Date: 2006-02-02 Impact factor: 21.405
Authors: Mario Castro; Adalberto Rubin; Michel Laviolette; Nicola A Hanania; Brian Armstrong; Gerard Cox Journal: Ann Allergy Asthma Immunol Date: 2011-04-14 Impact factor: 6.347
Authors: Mario Castro; Adalberto S Rubin; Michel Laviolette; Jussara Fiterman; Marina De Andrade Lima; Pallav L Shah; Elie Fiss; Ronald Olivenstein; Neil C Thomson; Robert M Niven; Ian D Pavord; Michael Simoff; David R Duhamel; Charlene McEvoy; Richard Barbers; Nicolaas H T Ten Hacken; Michael E Wechsler; Mark Holmes; Martin J Phillips; Serpil Erzurum; William Lunn; Elliot Israel; Nizar Jarjour; Monica Kraft; Narinder S Shargill; John Quiring; Scott M Berry; Gerard Cox Journal: Am J Respir Crit Care Med Date: 2009-10-08 Impact factor: 21.405
Authors: Tmirah Haselkorn; James E Fish; Robert S Zeiger; Stanley J Szefler; Dave P Miller; Bradley E Chipps; F Estelle R Simons; Scott T Weiss; Sally E Wenzel; Larry Borish; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2009-10-07 Impact factor: 10.793
Authors: Neil C Thomson; Adalberto S Rubin; Robert M Niven; Paul A Corris; Hans Christian Siersted; Ronald Olivenstein; Ian D Pavord; David McCormack; Michel Laviolette; Narinder S Shargill; Gerard Cox Journal: BMC Pulm Med Date: 2011-02-11 Impact factor: 3.317
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793